Shares of Medpace Holdings Inc (NASDAQ:MEDP) have been assigned an average rating of “Hold” from the ten analysts that are presently covering the firm, Marketbeat.com reports. Seven equities research analysts have rated the stock with a hold rating and three have given a buy rating to the company. The average 1 year price objective among brokerages that have updated their coverage on the stock in the last year is $37.25.
MEDP has been the subject of a number of research reports. Raymond James Financial initiated coverage on shares of Medpace in a research note on Friday, September 29th. They set a “market perform” rating for the company. Robert W. Baird restated a “hold” rating and set a $32.00 target price on shares of Medpace in a research note on Monday, October 9th. KeyCorp restated a “hold” rating on shares of Medpace in a research note on Tuesday, October 17th. Zacks Investment Research cut shares of Medpace from a “buy” rating to a “hold” rating in a research note on Tuesday, October 24th. Finally, William Blair cut shares of Medpace from an “outperform” rating to a “market perform” rating in a research note on Wednesday, November 1st. They noted that the move was a valuation call.
Shares of Medpace (MEDP) opened at $38.40 on Friday. The company has a debt-to-equity ratio of 0.36, a quick ratio of 0.68 and a current ratio of 0.68. The stock has a market cap of $1,440.00 and a PE ratio of 55.65. Medpace has a 12 month low of $21.76 and a 12 month high of $39.64.
In other Medpace news, major shareholder Medpace Limited Partnership sold 4,600,000 shares of Medpace stock in a transaction dated Tuesday, December 5th. The shares were sold at an average price of $30.16, for a total value of $138,736,000.00. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is available at the SEC website. 25.80% of the stock is owned by insiders.
Institutional investors have recently modified their holdings of the business. Acadian Asset Management LLC raised its position in shares of Medpace by 6.9% in the 4th quarter. Acadian Asset Management LLC now owns 633,743 shares of the company’s stock valued at $22,979,000 after buying an additional 40,944 shares in the last quarter. Alpha Windward LLC acquired a new position in shares of Medpace in the 4th quarter valued at approximately $513,000. Schwab Charles Investment Management Inc. raised its position in shares of Medpace by 96.9% in the 4th quarter. Schwab Charles Investment Management Inc. now owns 58,066 shares of the company’s stock valued at $2,106,000 after buying an additional 28,581 shares in the last quarter. Atria Investments LLC acquired a new position in shares of Medpace in the 4th quarter valued at approximately $211,000. Finally, Susquehanna International Group LLP raised its position in shares of Medpace by 30.9% in the 3rd quarter. Susquehanna International Group LLP now owns 9,947 shares of the company’s stock valued at $317,000 after buying an additional 2,347 shares in the last quarter. Institutional investors and hedge funds own 16.80% of the company’s stock.
Medpace Company Profile
Medpace Holdings, Inc is a clinical contract research organization. The Company provides clinical research-based drug and medical device development services. The Company partners with pharmaceutical, biotechnology, and medical device companies in the development and execution of clinical trials. The Company’s drug development services focus on full service Phase I-IV clinical development services and include development plan design, coordinated central laboratory, project management, regulatory affairs, clinical monitoring, data management and analysis, pharmacovigilance new drug application submissions, and post-marketing clinical support.
Receive News & Ratings for Medpace Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Medpace and related companies with MarketBeat.com's FREE daily email newsletter.